Edoxaban in Peripheral Arterial Disease (ePAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01802775
Recruitment Status : Completed
First Posted : March 1, 2013
Results First Posted : January 12, 2018
Last Update Posted : January 12, 2018
UMC Utrecht
Information provided by (Responsible Party):
Daiichi Sankyo, Inc.

February 25, 2013
March 1, 2013
December 11, 2017
January 12, 2018
January 12, 2018
February 6, 2013
December 3, 2014   (Final data collection date for primary outcome measure)
  • Percentage of Participants With Clinically Relevant Bleeding During Treatment [ Time Frame: at 3 months ]
    Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH)
  • Percentage of Participants With First Re-stenosis / Re-occlusion [ Time Frame: within 6 months ]
    Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant
  • bleeding events [ Time Frame: 6 months ]
    The proportion of subjects with major, major or clinically relevant non-major and all bleedings at 6 months.
  • proportion of patients with re-stenosis/re-occlusion [ Time Frame: 6 months ]
    The difference in proportions of patients with re-stenosis/re-occlusion at the treated segments(s)/s between treatment groups at 6 months.
Complete list of historical versions of study NCT01802775 on Archive Site
  • Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment [ Time Frame: within 3 months ]
    The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months
  • Safety Assessments [ Time Frame: within 6 months ]

    Number of participants with serious adverse events (SAEs) within 6 months

    Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality.

  • Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period [ Time Frame: within 6 months ]
    Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death
  • Number of Participants With Amputations [ Time Frame: within 6 months ]
    Number of participants with amputations within 6 months
  • bleeding events [ Time Frame: 6 months ]
    The proportion of subjects with major, major or clinically relevant non-major and all bleedings at 6 months will be estimated for each treatment group and summarized with 95% CI. The difference in the proportion between the two groups at each of the time points will be estimated with a 95% confidence interval (CI).
  • any bleeding [ Time Frame: 6 months ]
    number of subjects with any bleeding (major, clinically relevant non-major, and minor bleeding) occurring during treatment or within 3 days of interrupting or stopping study drug
  • safety assessments [ Time Frame: 6 months ]
    number of clinical and laboratory safety events with description of event including adverse events (AEs), serious adverse events (SAEs), and other events of special interest (i.e., hepatic events).
  • Major Adverse Cardiovascular Events [ Time Frame: 6 months ]
    number of Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI)/non-fatal stroke and death from cardiovascular causes
  • amputations [ Time Frame: 6 months ]
    number of amputations and description of event
  • all cause mortality [ Time Frame: 6 months ]
    number of all cause mortalities and description of event
Not Provided
Not Provided
Edoxaban in Peripheral Arterial Disease
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention
This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential efficacy of adding edoxaban to aspirin following femoropopliteal endovascular intervention, with or without stent placement, relative to current treatment practice with clopidogrel and aspirin.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Peripheral Arterial Disease
  • Drug: edoxaban
  • Drug: Clopidogrel
    75mg tablet
    Other Name: Plavix
  • Drug: Aspirin
  • Experimental: edoxaban/aspirin
    Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
    • Drug: edoxaban
    • Drug: Aspirin
  • Active Comparator: clopidogrel/aspirin
    Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis).
    • Drug: Clopidogrel
    • Drug: Aspirin

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
December 3, 2014
December 3, 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subjects older than the minimum legal adult age (country specific);
  • Rutherford stages 2-5 provided there are no ulcerations on the heel and/or exposed tendon and/or bone;
  • Superficial femoral above knee-popliteal ( 3 cm proximal to the medial femoral condyle) lesion and ≥ 50% stenosis or occlusion;
  • At least one run-off vessel to the foot with or without additional endovascular intervention;
  • Successful intervention, defined as angiographic confirmation of ≤ 30% residual stenosis and absence of flow limiting dissection;
  • Adequate hemostasis at the vascular access site within 24 hours of intervention;
  • A subject is also eligible if they have undergone additional successful endovascular intervention(s) during the index intervention;
  • Able to provide signed informed consent.

Exclusion Criteria:

  • Calculated Creatinine Clearance < 30 ml/min;
  • Femoral or popliteal aneurysm;
  • Adjunctive use of thrombolytics;
  • Any extravasation or distal embolization not successfully treated;
  • Uncontrolled hypertension as judged by the investigator (e.g., systolic blood pressure > 170 mmHg or diastolic blood pressure > 100 mmHg despite antihypertensives);
  • Aspirin intolerance;
  • Clopidogrel intolerance;
  • Contraindication for anticoagulants or antiplatelets and any other contraindication listed in the local labeling of aspirin and/or clopidogrel;
  • Active bleeding or known high risk for bleeding or history of intracranial, or spontaneous intraocular, spinal retroperitoneal or intra-articular bleeding; overt gastrointestinal (GI) bleeding or active ulcer within the previous year;
  • Subjects receiving dual antiplatelet or anticoagulant therapy at the time of randomization; subjects receiving pre-interventional loading dose of clopidogrel or other P2Y12 receptor antagonists;
  • Treatment with cilostazol within 24 hours of randomization;
  • Subjects receiving prohibited concomitant medications [fibrinolytics, chronic use of non steroidal anti-inflammatory drugs (NSAIDS) > 4 days per week, and oral or parenteral non-aspirin NSAIDs and strong P-gp inhibitors];
  • Prior stroke or myocardial infarction (MI) or acute coronary syndrome within 3 months;
  • Chronic liver disease [alanine transaminase (ALT) and/or aspartate transaminase (AST) ≥ 2 × upper limit of normal; total bilirubin (TBL) ≥ 1.5 × upper limit of normal]; however, subjects whose elevated TBL is due to known Gilbert‟s syndrome may be included in the study;
  • Prior history of a positive test for Hepatitis B antigen or Hepatitis C antibody;
  • Subjects who received any investigational drug or device within 30 days prior to randomization, or plan to receive such investigational therapy during the study period;
  • Subjects previously randomized to an edoxaban (DU-176b) study;
  • Women of childbearing potential without proper contraceptive measures (i.e. a method of contraception with a failure rate < 1 % during the course of the study including the observational period) and women who are pregnant or breast feeding;
  • Subjects with the following diagnoses or situations:

Active malignancy except for adequately treated non-melanoma skin cancer or other non-invasive or in-situ neoplasm (e.g., cervical cancer in situ); Concurrent treatment with cancer therapy (drugs, radiation, and/or surgery); Other significant active concurrent medical illness or infection; Life expectancy < 12 months;

  • Subjects who are unlikely to comply with the protocol (e.g., uncooperative attitude, inability to return for subsequent visits, and/or otherwise considered by the Investigator to be unlikely to complete the study);
  • Subjects with any condition that, in the opinion of the Investigator, would place the subject at increased risk of harm if he/she participated in the study;
  • History of heparin-induced thrombocytopenia
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Austria,   Belgium,   Germany,   Israel,   Netherlands,   Switzerland,   United States
2012-003009-88 ( EudraCT Number )
Not Provided
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address:
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Clinical Study Report (CSR)
Supporting Materials: Analytic Code
Time Frame: Studies for which the medicine and indication have received EU and US marketing approval on or after 01 January 2014 or by the US or EU Health Authorities when regulatory submissions in both regions are not planned and after the primary study results have been accepted for publication.
Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States and the European Union from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc.
UMC Utrecht
Study Director: Global Clinical Leader Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc.
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP